E3818BAA-BA28-4CE4-A745-BB3692883888
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 48.29172141918528
- age_years
- 39
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.499
- OXIDATIVE_PHOSPHORYLATION+0.285
- UV_RESPONSE_DN+0.270
- MTORC1_SIGNALING+0.267
- TGF_BETA_SIGNALING+0.258
- WNT_BETA_CATENIN_SIGNALING+0.249
- HEDGEHOG_SIGNALING+0.244
- MYC_TARGETS_V1+0.238
- MYC_TARGETS_V2+0.215
- MITOTIC_SPINDLE+0.194
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.453
- INTERFERON_ALPHA_RESPONSE-0.432
- INTERFERON_GAMMA_RESPONSE-0.431
- TNFA_SIGNALING_VIA_NFKB-0.430
- ALLOGRAFT_REJECTION-0.399
- ANGIOGENESIS-0.356
- IL2_STAT5_SIGNALING-0.316
- INFLAMMATORY_RESPONSE-0.312
- APOPTOSIS-0.295
- COAGULATION-0.283
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BAA2D0D4-DD8C-4F80-8D37-986AFC578536 | — | — | 0.899 |
| 2 | 9F204EEA-9026-4367-8586-C2127D55AC5E | — | — | 0.888 |
| 3 | 713B4DA5-FA8A-4E52-BACF-19B912467FBB | — | — | 0.883 |
| 4 | EF7D394C-BAB6-4826-AE09-9E5E884E0023 | — | — | 0.870 |
| 5 | 0D8C7EC1-9BFB-44A1-8AF8-05D2A6BBE0F9 | — | — | 0.868 |
| 6 | ERR2598195 | fetal | fetal | 0.859 |
| 7 | D47BE4CF-FF4F-4422-89AE-9AFAE192309C | — | — | 0.857 |
| 8 | 9E2420C3-FD2A-45BB-B5A3-DC25D9F7CB3C | — | — | 0.857 |
| 9 | 4549956C-8D25-4B37-894C-E82D5C7684F0 | — | — | 0.852 |
| 10 | A770E81F-8898-4632-A839-7950EED7CF7A | — | — | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.499 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.285 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.267 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.258 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.249 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.244 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.238 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.215 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.194 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.179 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.167 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.148 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.134 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.127 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.101 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.094 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.061 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |